阿尔茨海默相关脑改变可能影响ALS患者预后
Alzheimer-related changes in the brain may affect prognosis in ALS
瑞典、日本和意大利研究者分析264例ALS患者的脑脊液,发现约14%存在阿尔茨海默相关的淀粉样蛋白变化;该变化会增强高神经丝轻链NfL与较短生存期的关联,并在意大利153例队列中获支持。模型整合NfL与淀粉样蛋白 biomarker 可改善ALS识别,但结果基于观察性数据,还不能用于临床决策,需进一步验证。
Amyotrophic lateral sclerosis (ALS) is a serious neurodegenerative disease in which the nerve cells that control the body's muscles break down. The course of the disease varies greatly. While some patients deteriorate rapidly, others live considerably longer with the disease. This makes it difficult to assess at an early stage how the disease will progress.
Coexisting pathological changes in the brain are known to occur in ALS, but their association with disease progression has remained unclear. In a collaboration between Sweden, Japan and Italy, the researchers investigated how Alzheimer-related changes affect prognosis in ALS.
"Lund University conducts leading research into Alzheimer's disease, while Nagoya University has a strong ALS research program. As I am a doctoral student at both universities, the idea arose to bring the two fields of research together in this study," says Kazuki Obara, who is also a neurologist in Japan.
To investigate whether and how coexisting Alzheimer-related changes in the brain affect the course of ALS, the researchers analyzed levels of amyloid beta in cerebrospinal fluid in Japanese patient cohorts. Amyloid beta is used as a biomarker of changes associated with Alzheimer's disease.
The study is published in the journal eBioMedicine.
A total of 264 patients with ALS were included, 60% of whom were men and 40% women, with a mean age of 67 years. The control group consisted of 164 patients with other neurological diseases.
"We found that around 14% of the patients with ALS showed signs of changes that also occur in Alzheimer's disease," Obara continues.
The researchers also studied NfL (neurofilament light chain), a biomarker with applications that include measuring nerve cell damage in ALS. The findings showed that the presence of amyloid beta–related changes modified the association between NfL and disease progression.
In the amyloid beta–positive group, the association between high NfL levels and shorter survival was stronger than in the amyloid beta–negative group. The findings were supported by additional data from 153 patients with ALS in Bologna, Italy. The researchers also observed an interaction between amyloid beta and NfL with regard to a decline in everyday physical function over time.
"The findings suggest that the same NfL level may have different prognostic significance depending on what other changes are present in the brain. One possible explanation is that several disease processes together make the nervous system more vulnerable, but the underlying mechanisms have not yet been established," says Niklas Mattsson-Carlgren, a researcher at Lund University and consultant neurologist at Skåne University Hospital.
Improved identification of ALS
The researchers also tested machine-learning models that combined NfL with other biomarkers, including amyloid beta. The models improved the identification of ALS, including in people whose NfL values fell within a gray area. In time, NfL could be used in an initial assessment. If the result is unclear, the analysis could be supplemented with additional biomarkers and a more detailed clinical examination.
The aim is to provide doctors with a better basis both for diagnosing ALS and for assessing the course of the disease, so that they can discuss what to expect with patients and their families.
"A more detailed prognosis may also be valuable in clinical trials. If participants with very different expected disease courses are included in the same study, it becomes more difficult to determine whether a treatment has an effect. Biomarkers may therefore contribute to better patient stratification and more efficient studies of new treatments," says Mattsson-Carlgren.
The study is based on observational data, and the findings cannot yet be used as a basis for clinical decisions. The methods also need to be confirmed in further independent patient groups.
The researchers are now proceeding to investigate whether biomarkers linked to other neurodegenerative diseases, such as Parkinson's disease, may also affect prognosis in ALS.
Publication details
Kazuki Obara et al., Cerebrospinal fluid amyloid and neurodegeneration biomarkers in the diagnosis and prognosis of amyotrophic lateral sclerosis: a multicohort observational study, eBioMedicine (2026). DOI: 10.1016/j.ebiom.2026.106511
Journal information: EBioMedicine
Clinical categories
Who's behind this story?
Sadie Harley
BSc Life Sciences & Ecology. Microbiology lab background with pharmaceutical news experience in oil, gas, and renewable industries. Full profile →
Robert Egan
Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →
Citation: Alzheimer-related changes in the brain may affect prognosis in ALS (2026, October 21) retrieved 21 October 2026 from https://medicalxpress.com/news/2026-10-alzheimer-brain-affect-prognosis-als.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
来源:Medical Xpress · medicalxpress.com